Terns Pharmaceuticals, Inc. P/B ratio

P/B ratio of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of Terns Pharmaceuticals, Inc. is 1.11 (as of December 31, 2021)
  • P/B ratio for the quarter ending December 31, 2021 was 1.11
  • Annual P/B ratio for 2021 was 1.11
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Terns Pharmaceuticals, Inc.

Most recent P/B ratioof TERN including historical data for past 10 years.

Interactive Chart of P/B ratio of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 1.11 1.11

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.